eMQT

Expected to reach 3-5 billion by 2020 representing half of the world's population, Africa's population offers access to drug naïve patients in multiple disease areas as well as an underrepresented demographic in clinical trials. eMQT is uniquely placed as the bridge between the pharmaceutical, Biotechnology and Technology industries and Africa, utilizing research healthcare experts and technology enabled innovation to provide access to patients, high quality evidence based patient data and ultimately patient access to medicines.